A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER-2 Negative Breast Cancer and an Oncotype Recurrence Score < 25
Protocol: NRG-BR009 SCHEMA NRG-BR009 Please Note: Below is a brief description of eligibility, please contact the Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079 or (810)762-8038 to discuss the full eligibility requirements. Eligibility: Female patients must be ≥ 18 years of age. Patients must be premenopausal (evidence of functioning ovaries) at the time of […]
A Randomized Phase III Study of Shorter Anthracycline Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer
Protocol: SWOG – S2212 SCHEMA S2212 Please Note: Below is a partial list of eligibility, please contact the Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079 or (810)762-8038 to discuss complete eligibility requirements. Thank you! Eligibility: Participants must have histologically confirmed ER-negative, PR-negative, and HER2-negative breast cancer (TNBC) defined as ER<5%, PR<5%, and HER2 […]
An Open Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER-2 Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
Protocol: NSABP-FB-12 SCHEMA NSABP FB-12 Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! Patient Guidelines: Medical oncologist has indicated the intention to administer doxorubicin/cyclophosphamide followed by paclitaxel. Co-morbid conditions should be taken into consideration, but not the diagnosis […]
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER-2 Positive Breast Cancer): CompassHER2 Residual Disease, A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Protocol: Alliance – A011801 SCHEMA A011801 Please Note: Below is a partial list of eligibility, please contact GHCI Research Department at (810)762-8181, (810)762-8079, (810)762-8038 to discuss full eligibility requirements. ELIGIBILITY: HER2-positive breast cancer, will be based on pre-treatment biopsy material and defined as an immunohistochemistry (IHC) score of 3+ and/or positive by in situ hybridization […]